DDInter1388 DDInter1940
Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome. It can also be found in quadruple regimens for the treatment of _H. pylori_ infections along with other antibiotics including [amoxicillin], [clarithromycin], and [metronidazole], for example. Its efficacy is considered similar to other medications within the PPI class including [omeprazole], [esomeprazole], [lansoprazole], [dexlansoprazole], and [rabeprazole]. Pantoprazole exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups
Vismodegib is an orally active small molecule that inhibits the hedgehog signaling pathway by binding to and inhibiting the transmembrane protein smoothened homologue (SMO).[A258613,A258618,L45803] It was discovered by high-throughput screening of a library of small-molecule compounds and subsequent optimization through medicinal chemistry. Since it targets the hedgehog signaling pathway, vismodegib has anti-tumor activity in basal-cell carcinoma. The Hedgehog signaling pathway plays an important role in the development of organs and tissues during embryogenesis. Afterwards, it is silenced in all cells and tissues, except for hair, skin and stem cells. However, dysregulated or aberrant Hedgehog signaling has been associated with basal cell carcinoma pathogenesis.[A258608,L45803] In January 2012, vismodegib was approved by the FDA for the treatment of adult basal cell carcinoma. In July 2013, it was approved by the EMA, and since then, it has been approved by several other countries.[A7370,A258618,L45803]
Pantoprazole {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Vismodegib
Pantoprazole {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Vismodegib
Pantoprazole {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Vismodegib
Pantoprazole {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Sulfasalazine
Sulfasalazine {u} (Compound) resembles {v} (Compound) Vismodegib
Pantoprazole {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Vismodegib
Pantoprazole {u} (Compound) causes {v} (Side Effect) Dehydration
Dehydration {u} (Side Effect) is caused by {v} (Compound) Tolvaptan
Tolvaptan {u} (Compound) resembles {v} (Compound) Vismodegib
Pantoprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capmatinib
Capmatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sulfasalazine
Sulfasalazine {u} (Compound) resembles {v} (Compound) Vismodegib
Pantoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Amphotericin B
Amphotericin B {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sulfasalazine
Sulfasalazine {u} (Compound) resembles {v} (Compound) Vismodegib
Pantoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Amphotericin B
Amphotericin B {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Vismodegib
Pantoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Plazomicin
Plazomicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sulfasalazine
Sulfasalazine {u} (Compound) resembles {v} (Compound) Vismodegib
Pantoprazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Vismodegib (Compound)
Pantoprazole (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Vismodegib (Compound)
Pantoprazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sorafenib (Compound) and Sorafenib (Compound) resembles Vismodegib (Compound)
Pantoprazole (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Sulfasalazine (Compound) and Sulfasalazine (Compound) resembles Vismodegib (Compound)
Pantoprazole (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Sorafenib (Compound) and Sorafenib (Compound) resembles Vismodegib (Compound)
Pantoprazole (Compound) causes Dehydration (Side Effect) and Dehydration (Side Effect) is caused by Tolvaptan (Compound) and Tolvaptan (Compound) resembles Vismodegib (Compound)
Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Capmatinib and Capmatinib may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine (Compound) resembles Vismodegib (Compound)
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Amphotericin B and Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine (Compound) resembles Vismodegib (Compound)
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Amphotericin B and Amphotericin B (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Vismodegib (Compound)
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin and Plazomicin may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine (Compound) resembles Vismodegib (Compound)